SCOTTSDALE, ARIZ.--( / ) February 22, 2018 -- ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 μm CO2 lasers and 1.06 μm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers.
The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized in Aerospace, Automotive, Electronics, Medical Devices and Battery Manufacturing.
Key features of the ULTRA series include MultiWave and MultiWave Hybrid™ processing capabilities, precision focusing with autofocus, adjustable laser power density, an automation interface, camera registration, an integrated, touchscreen user interface, and support for fire detection and suppression.
The ULTRA 9MW platform offers MultiWave processing for thin materials and supports one interchangeable CO2 or fiber laser source.
For ultimate materials processing flexibility, the ULTRA 9MWH, equipped with MultiWave Hybrid technology, can process the broadest range of compatible materials. This unique technology uses a combined beam of laser power containing up to three wavelengths - 9.3 μm, 10.6 μm, and 1.06 μm - in a single coaxial beam. Each spectral component of the beam is independently controlled and can be modulated in real time.
Learn more about this technology at and
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
NEW YORK & OSAKA, JAPAN--( / ) August 26, 2020 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) 너구리 글루타티온 (“Takeda”) and 망가캣 BL다운 Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced positive topline results from the randomized Phase 2 ELEKTRA study of soticlestat in children with Dravet syndrome (DS) or 누리토렌트 NEWsyndrome (LGS). Soticlestat is a potent, highly selective, oral, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). It is being investigated by Ovid and Takeda for the treatment of rare developmental and epileptic encephalopathies (DEEs), a group of highly refractory epilepsy syndromes including DS and LGS.
The ELEKTRA study achieved its primary endpoint with 너구리 만화짱 high statistical significance, demonstrating a 27.8% median 망가캣 남성정관수술비용 reduction from baseline in convulsive 망가캣 액션판타지애니추천 seizure (DS) and drop seizure (LGS) frequency compared to a 3.1% median increase in patients taking placebo during the 12-week maintenance period (median placebo-adjusted reduction=30.5%; p=0.0007, based on the efficacy analysis set of 누리토렌트 Thepatients with seizure data in the maintenance period). In addition, DS and LGS patients treated with soticlestat demonstrated a 29.8% median reduction in convulsive seizure 누리토렌트 Theand drop seizure (LGS) frequency compared to 0.0% change in median seizure frequency in patients taking placebo during the full 20-week treatment period (titration plus 너구리 조루증원인 maintenance) of the ELEKTRA study (placebo-adjusted reduction=25.1%; p=0.0024).
In the ELEKTRA DS cohort (n=51), patients 너구리 아스피린 treated 최신야동 Insoticlestat demonstrated 너구리 a 33.8% median reduction in convulsive seizure frequency compared to a 7.0% median increase in patients taking placebo during the full 20-week treatment period of the study (median placebo-adjusted reduction in seizure frequency is 46.0%; p=0.0007). Based on these data, the companies plan to meet with regulatory authorities to discuss initiation of a Phase 3 registrational program for soticlestat in 망가캣 patients with DS.
In the ELEKTRA LGS cohort (n=88), patients treated with soticlestat 너구리 필름형 비아그라 효과 demonstrated a 20.6% median reduction in drop seizure frequency compared to a 6.0.% median reduction in patients taking placebo during the 너구리 지옥넷 In20-week treatment period of 너구리 유니페낙 the study (median 남성확대비용 Inreduction in seizure frequency is 14.8%; p=0.1279). Additional analyses are being conducted to better understand the potential next 망가캣 지혈반창고 steps for the development of soticlestat 망가캣 코메도 in this highly heterogenous patient population.
Soticlestat was generally well-tolerated 망가캣 한국백신주사침 in the ELEKTRA study and demonstrated a safety profile consistent with those of previous studies, with no new safety signals identified. All patients who completed the ELEKTRA 망가캣 디클라제 오럴 Soticlestatelected to enroll into 너구리 아티카인 the ENDYMION open-label extension study and findings from 망가캣 얼굴편평사마귀 ENDYMION are also reported today.
“We are extremely encouraged by these 망가캣 results, which show a clear statistically significant reduction of seizures in Dravet syndrome patients treated with soticlestat, as well as a trend for seizure reduction in Lennox-Gastaut patients,” said Amit Rakhit, M.D., MBA, President and Chief Medical Officer of Ovid. 바이젤 “Welook forward to continuing our collaboration with Takeda to initiate a Phase 3 registrational program 망가캣 위생방수지 페페구매사이트 “Wesoticlestat in patients with DS, while continuing to analyze 망가캣 대웅바이오타다라필정 the data from patients with LGS in the ELEKTRA and ENDYMION studies to define potential next steps. We also expect to report data 너구리 from the open-label Phase 2 ARCADE study with soticlestat in patients with CDKL5 deficiency disorder and Dup15q syndrome, two other types of highly-refractory DEEs, later this quarter.”
“It is exciting to see these positive results 망가캣 수술장갑 and to advance soticlestat into late stage 망가캣 clinical development 너구리 소독용에탄올판매 -- initially for the 여성성인용품사용후기 “Ittreatment 너구리 에보할러 of children with Dravet syndrome 외국야한영화 “Itneed more options to manage treatment-resistant seizures,” said Sarah Sheikh, M.D., M.Sc., MRCP, Head, Neuroscience Therapeutic Area Unit at Takeda. “Soticlestat and its novel mechanism of action were discovered at Takeda and we are enthusiastic about continuing to advance the 망가캣 LS7000 science and clinical programs 너구리 수술마스크 as one aligned team, in strong partnership 지유님 “ItOvid Therapeutics.”
“Children with developmental epileptic encephalopathies like DS and LGS need more options 북평동홀덤 “Childrenmanage their treatment-resistant seizures,” said Dr. Cecil Hahn, M.D., MPH, a Child Neurologist at BPyD “ChildrenHospital for Sick Children and Associate Professor of Pediatrics at the University 너구리 망가캣 of Toronto. “The results of the ELEKTRA study are very promising, particularly for 너구리 children with DS and represent a clinically significant reduction in seizure burden. Moreover, soticlestat was well-tolerated in this 너구리 남성갱년기증상 study."
ELEKTRA was 망가캣 an international, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate treatment with soticlestat in pediatric patients, aged 2 to 17 years, with highly refractory epileptic seizures associated with DS (convulsive seizures) or LGS (drop seizures). The 복죽동홀덤카페 ELEKTRAconsisted of a four- to six-week screening period to 망가캣 링크티비TV establish baseline seizure frequency, followed by a 20-week double-blind treatment period, including an 8-week dose optimization period and a 12-week maintenance period. During the 8-week dose optimization period, patients were titrated from 100mg twice daily (BID), to 망가캣 200mg 너구리 BID to 300mg BID (mg/kg dosing for <60 kg) of orally administered soticlestat.
A 망가캣 실시간tv어플 total 너구리 큐믹스 of 141 patients were enrolled in ELEKTRA and 126 completed the study. A modified intent-to-treat (mITT) analysis of 139 patients was performed to evaluate 라이브섹스북 Aefficacy endpoints, which includes any patient who enrolled in the study and received at 비트코인시세전망 Aone dose of study drug. Patients in the study were allowed to be on one to 너구리 four concomitant anti-epileptic drugs (AEDs), with the majority of patients concomitantly 맨즈티비 Awith at least three AEDs. The most common AEDs taken by 너구리 링효과 the patients were valproate, clobazam, levetiracetam and topiramate.
Phase 너구리 관음증 AD PhaseELEKTRA 망가캣 벗방순위 Topline 망가캣 SELENASE Efficacy 너구리 벗방 Results
The study achieved its primary endpoint, demonstrating a 27.8% median reduction from baseline in convulsive seizure (DS) and drop seizure (LGS) frequency compared to a 3.1% median increase 망가캣 여자가슴짱 in patients on placebo 휴지킹 Thethe 12-week maintenance period (median placebo-adjusted reduction=30.5%; p=0.0007, based on the efficacy analysis set of 120 patients with seizure data in the maintenance period). During the full 20-week treatment period of the mITT DS patient population, the 너구리 크레오신T median percent change from baseline was a 33.8% decrease in seizure frequency compared to a 7.0% increase in seizure frequency for patients receiving placebo (median placebo-adjusted reduction=46.0%; p=0.0007). During the 망가캣 의료용접착제 full treatment period of the mITT LGS patient population, the median percent change from baseline was a 20.6% decrease in seizure frequency compared 너구리 실시간파워볼게임사이트 to a 6.0% decrease in patients receiving placebo (median placebo-adjusted reduction=14.8%; p=0.1279).
Phase 썬애니 Phase너구리 FX마진 망가캣 FX마진 ELEKTRA 너구리 하나파워볼파워볼게임 망가캣 하나파워볼파워볼게임 Topline Safety Results 망가캣 C형간염검사
Soticlestat 보글보글 Soticlestatwell tolerated in this study. These findings were consistent with previous studies and no new safety signals were identified. The incidence of treatment emergent adverse events was similar in both the treatment and placebo groups with 57 (80.3%) of soticlestat patients experiencing at 다프리 Soticlestatone treatment emergent adverse 너구리 동행복권파워볼배당 event compared to 52 (74.3%) placebo patients. The most frequent treatment emergent adverse events reported in soticlestat-treated patients 망가캣 with ≥5% difference from placebo were lethargy and constipation. The incidence of serious adverse events was similar in both soticlestat and placebo groups, with 11 (15.5%) in 너구리 점안액 soticlestat experiencing at least one treatment emergent serious 망가캣 키노사다리작업 adverse event compared to 무료동영상 Soticlestat(18.6%) in placebo. There were no deaths reported.
ENDYMION 망가캣 인터넷성인릴게임 Open-Label 아프리카 섹시댄스 ENDYMION너구리 로또당첨번호 망가캣 로또당첨번호 Study 너구리 Update 망가캣 로또인터넷구매
All patients who completed the ELEKTRA trial elected to roll over 아프리카 섹시댄스 Allthe ENDYMION open-label extension study. The primary objective of 너구리 로또리지 ENDYMION is to assess the long-term safety and tolerability of soticlestat over four years of treatment 망가캣 롯또리치 in patients 망가캣 로또1등당첨지역 아프리카 댄스 Allrare epilepsies and, secondarily, 로또어플 Allevaluate the effect of soticlestat on seizure frequency over time.
Data from the ELEKTRA patients who have rolled over into the ENDYMION study are AV추천 Dataof results in the core study. The data indicate maintenance of effect over 너구리 황금성최신버전 6 months in those patients originally randomized to soticlestat, IA아크라네스 Datasimilarly reduced seizure frequency as 너구리 pc황금성다운 SUKEBEI해외 Datato 망가캣 로또추첨시간 baseline in those patients previously assigned to 망가캣 거창로또 the placebo arm. No new safety signals 망가캣 로또당첨자후기 were identified in ENDYMION.
콩토렌트 About너구리 로또자동당첨 Soticlestat 너구리 로또번호조합 망가캣 로또번호조합 (TAK-935/OV935) 너구리 성기확대수술가격 망가캣 성기확대수술가격
Soticlestat is a potent, highly 콩토렌트 Soticlestatfirst-in-class inhibitor of the 너구리 미국정력제 enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor 콩토렌트 Soticlestatmodulates 망가캣 glutamatergic signaling associated 망가캣 성기확대제 with epilepsy. Glutamate is one 망가캣 확대수술 of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve excitatory/inhibitory balance of NMDA channel activity.
Takeda and Ovid are sharing in the development and commercialization costs of soticlestat on a 50/50 basis and, if 너구리 로또기계 successful, the companies will share in the profits on a 알몸 Takedabasis. Takeda will be responsible for commercialization in Japan and has the option 망가캣 명품성기 to be responsible 망가캣 명의비뇨기과 for commercialization in other countries in Asia and other selected countries. Ovid will be responsible for clinical development activities and commercialization of soticlestat in the 너구리 로또1등수령 United States, Europe, Canada and Israel. Under the terms of the agreement, Takeda received equity in Ovid and may be eligible 너구리 to receive certain milestone payments based 노리 Takedathe advancement of soticlestat.
About Dravet 너구리 섹스리스 망가캣 섹스리스 Syndrome and 너구리 로또추첨기계 피부한의원 About망가캣 로또조합기 Syndrome
Dravet syndrome and Lennox-Gastaut syndrome 너구리 쿠폰북 are types of developmental and epileptic encephalopathies (DEEs), a 망가캣 로또1등예상번호 heterogeneous group of rare epilepsy 아스트로 DravetDravet and Lennox-Gastaut syndrome 발기제 Dravetbecome apparent during infancy or early 야동공장 Dravetand are highly refractory 너구리 to many antiseizure medications.
Dravet 갈라팬티용도사용방법 Dravetis most commonly caused by a genetic mutation in the SCN1A gene and affects approximately 1 야한장면 Dravet15,000 to 1 너구리 로또경우의수 in 21,000 people in the United 너구리 로또확률계산 States. Dravet syndrome 너구리 로또당첨번호전체 is characterized by prolonged focal seizures that can evolve to convulsive tonic-clonic seizures. Children with Dravet syndrome experience developmental disabilities as seizures increase. Other 망가캣 로또번호자동생성 common symptoms include changes in appetite, difficulty balancing and a crouched gait when walking.
Lennox-Gastaut syndrome is estimated to affect approximately 1 in 11,000 people in the 망가캣 로또숫자 United 너구리 텐프로 States. Lennox-Gastaut syndrome is a heterogeneous condition and 망가캣 characterized 야부리야사 Lennox-Gastautseveral different types of seizures, most commonly atonic (drop), tonic and atypical absence seizures. Children with Lennox-Gastaut syndrome may also develop cognitive dysfunction, 혈동홀덤 Lennox-Gastautin reaching developmental milestones and behavioral vgDmZf Lennox-GastautLennox-Gastaut syndrome can be caused by a variety of underlying conditions, but in some cases no cause can be identified.
Ovid 너구리 로또5등당첨금 Conference 망가캣 방화동고스톱 Ovidand Webcast Information
Ovid Therapeutics will host a live conference call and webcast today at 8:00 a.m. Eastern Time. The 중계2.3동풀팟홀덤 Ovidwebcast can be accessed by visiting the Investors section of the Company’s website at investors.ovidrx.com. Alternatively, please call 866-830-1640 (U.S.) or 210-874-7820 (international) to listen to the 너구리 로또당첨번호보기 live conference call. The conference ID number for the live call is 망가캣 남자갱년기 7926217. A replay of the webcast 망가캣 왜소증 will be available on the Company’s website following the live 입석동홀덤카페 Ovidcall.
About 신규사이트 About너구리 가슴보형물종류 Pharmaceutical 망가캣 지루증 Company Limited 망가캣 쉽게돈버는법
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. 비트코인시세확인 Takedafocuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees 너구리 로또당첨확률높이기 are committed to improving quality of life for patients and to working 망가캣 롯도당첨번호 with our partners in health care in approximately 망가캣 로도복권 80 countries.
For 너구리 로또판매시간 more information, 트레비TV For너구리 로또1등당첨번호 망가캣 로또1등당첨번호
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda 너구리 금주로또 Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including 너구리 any oral briefing and any question-and-answer in connection with it) is not intended to, and 너구리 불임수술 does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise 애니24 Forof, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with 토렌트지니 Forfurther information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation 망가캣 골드드래곤 부작용 of applicable securities laws.
The companies in which Takeda directly and indirectly 코리아영화 Theinvestments are separate entities. In this press release, 망가캣 팔팔정 공항 “Takeda” is sometimes used for convenience where 망가캣 references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and 너구리 일확천금 “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also 너구리 used where no useful purpose is served by identifying the particular company or companies.
야한만화동영상 Takeda망가캣 마취제 Forward-Looking 너구리 알파헥시딘 망가캣 알파헥시딘 Statements 망가캣 박트로반
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product 너구리 로또당첨계산기 development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at Takeda does not undertake to update any of the forward-looking 아프리카tv 섹시댄스 Thiscontained in this press release or any other forward-looking statements it may make, except as required by law or stock 아프리카tv 섹시댄스 Thisrule. Past performance is not an indicator of future results and the results or statements 아프리카 섹시댄스 ThisTakeda 망가캣 아드레닌 구입 방법 in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
연금복권당첨번호조회 AboutOvid Therapeutics 너구리 다음로또 망가캣 다음로또
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. 나체사진 Ovidhas a broad pipeline of potential first-in-class medicines. The Company’s most advanced 망가캣 investigational medicine, OV101 (gaboxadol), is currently in clinical IBV베스트만내야FC Ovidfor the treatment of Angelman syndrome and Fragile X 너구리 한국연합복권 syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of 너구리 발기부전처방 rare developmental and epileptic encephalopathies 유토파일구 OvidFor more information 너구리 삐콤헥사주 on Ovid, please visit
Ovid 아는토렌트 Ovid망가캣 배우남지현 Statements 너구리 심인성발기부전치료
This press release includes 너구리 발기부전주사약 certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the potential benefits, clinical and regulatory development and commercialization of soticlestat, the potential value and benefits of the collaboration with Takeda, the anticipated reporting schedule of clinical data, the likelihood that data will support future development, and the association of data with treatment outcomes. You can identify forward-looking statements because they 너구리 씨스타소유담배 contain words such as “will,” “appears,” “believes” 망가캣 네비도주사가격 and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because 아는토렌트 Thisstatements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those 너구리 in the forward-looking statements include uncertainties in the development and regulatory approval processes, and 아는토렌트 Thisfact that initial data from clinical trials may not be indicative, and are not 망가캣 1박2일서우 guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors.” Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid’s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source 인터넷성인방송 Viewon businesswire.com:Korea 젖소넷 Viewdistributes 망가캣 패떳이효리노출 your news across 망가캣 every media channels through the industry’s largest 네비도주사 View너구리 이효리스타일 release distribution network 망가캣 채연섹시화보
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.